ClinicalTrials.gg
CompletedNCT05651061Updated Aug 22, 2023

A Phase I of SS109 in Hemophilia A or and B With Inhibitors

A Phase 1 interventional study of SS109 in Hemophilia A With Inhibitor, Hemophilia B With Inhibitor and Factor VII Deficiency, sponsored by Jiangsu Gensciences lnc.. Completed at 10 sites in China. Open to male participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2023-08-22.

Sponsored by Jiangsu Gensciences lnc. · Phase 1, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
27
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
Male
01

Study summary

This phase I study aims to evaluate the safety, PK/PD and immunogenicity of SS109 in hemophilia A or and B with inhibitors. Twenty -seven patients are enrolled in study, and divided into five dose cohorts, from 30μg/kg to 360μg/kg. Dose 1 cohort enrolls three patients, each other dose cohorts enroll six patients. All patients included in the study will continue to be followed up until 28 days after SS109 administration.

Read the detailed description

This study is an open label, dose escalation, multicenter clinical trial. The study sets up a science review committee to assess the dose escalation. Serial blood samples for PK/PD analysis will be taken up to 72 hours after SS109 injection. Patients safety will be routinely monitored throughout the study.

02

Conditions studied

  • Hemophilia A With Inhibitor
  • Hemophilia B With Inhibitor
  • Factor VII Deficiency
03

In context

Lead sponsor

Jiangsu Gensciences lnc. is the lead sponsor of 6 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age was 18 to 65 years old,when signing the form, male;
  2. Clinical diagnosis of hemophilia A or B (previous or screening period FⅧ activity level≤ 1% or FⅨ activity level≤ 2%), and there is one of the following conditions:

    • FⅧ or FⅨ inhibitor level ≥ 5Bu/mL during screening period;
    • During the screening period, the level of FⅧ and FⅨ inhibitors was less than 5 Bu/mL and more than 0.6 Bu/mL, but had a high response to factor Ⅷ or IX injection (such as, the patient had a positive history of FⅧ/FⅨ inhibitors, and then the inhibitor level is ≥ 5Bu/mL, after the second infusion of FⅧ/FⅨ);
  3. No active bleeding symptoms before the first injection;
  4. Patients can comply with the requirements of the protocol and be willing to complete the study as planned and provide biological samples for test;
  5. Be able to understand the procedures and methods of this clinical trial. The patient voluntarily participates and signs by himself or by the impartial witness

Exclusion criteria

Exclusion Criteria:

  1. Patients with known history of to the drug preparation and any of its components;
  2. There was hypersensitivity or anaphylaxis after FⅦ or IgG2 injection treatment in the past;
  3. Patients with FⅦ inhibitor positive or with FⅦ inhibitor positive history in screening period;
  4. Severe anemia ( \< 60g/L);
  5. count \< 100 × 109/L;
  6. Patients with abnormal liver and kidney functions: (ALT) or aspartate aminotransferase (AST)≥ 2.5 times the value (ULN), or total ≥ 1.5 times ULN; or blood creatinine (Cr) ≥ 1.5 times;
  7. One or more tests are positive, such as , antibody, anti-human immunity for antibody and anti-treponema pallidum specific antibody (TPHA);
  8. Except for hemophilia A or B, the coagulation indexes of any other bleeding disease or other diseases are obviously different(such as platelet disease, vitamin K deficiency, etc.);
  9. History or symptoms of any previous arterial or venous thromboembolism event (such as atherosclerosis, myocardial infarction, ischemic stroke, , deep vein thrombosis or pulmonary hypertension, pulmonary embolism), or patients with history of disseminated intravascular coagulation (DIC);
  10. Suffered from serious heart disease, such as unstable angina, congestive heart failure (, ≥ Grade III), severe arrhythmia (>450ms, corrected by Fridericia formula), hypertension (systolic blood pressure ≥ 160 mmHg or diastolic blood pressure ≥ 95 mmHg) not controlled by treatment;
  11. Receive any product containing FⅦ or FⅦa (plasma derived or recombinate) within 48 hours before the first injection;
  12. Receive any product containing FⅧ (plasma derived or recombinate) within 72 hours before the first injection; or receive any product containing FIX (plasma derived or recombinate) within 96 hours before administration;
  13. Patients have used any anticoagulant, anti-fibrinol solvent, chemical, biological products or traditional Chinese medicine that affect platelet function within one week before the first injection or need to use any anticoagulant, anti-fibrinol solvent during PK/PD period, including non-steroidal anti-inflammatory drugs (NSAIDs) such as aspirin;
  14. Patients have received immunomodulator (such as gamma globulin α- Interferon and prednisone>10mg/d [and>7 days] or similar drugs, except antiretroviral drugs);
  15. Patients who received whole blood or plasma treatment within 2 weeks before the first injection;
  16. Patients who have received vaccines within 4 weeks or planned to be vaccinated during the trial before the first injection;
  17. Major surgery (such as orthopedic surgery and abdominal surgery) was performed within 1 month before the first injection, or planned to undergo surgery during the study;
  18. Patients who have been selected into other clinical trials within 1 month before the first injection;
  19. Patients with a history of drug abuse or alcohol abuse (alcohol abuse standard: male with a long-term alcohol consumption history of more than 5 years, equivalent to alcohol ≥ 40g/d, ≥ 20g/d for women, or a history of heavy drinking within 2 weeks, with the equivalent alcohol volume > 80g/d.
  20. Patients suffering from mental illness or obvious mental disorder, or incapacity and lack of cognition caused by other reasons
  21. A birth plan or sperm donation plan from the study to 3 months after the study, or patients are unwilling to take measures (such as condoms, diaphragms, intrauterine devices, etc.);
  22. A disease with clinical significance or other reasons that the researcher thinks patients are not suitable for participating in this clinical trial (if patients cannot benefit from clinical trials);
  23. The investigator considers patients with poor compliance, and patients will be impossible to evaluate the efficacy or accomplish the course of treatment and follow-up.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
27 participants (actual)

Study arms

  • Experimental
    Dose cohorts

    Dose cohorts were designed to evaluate the safety, immunogenicity and PK/PD.

    Biological: SS109

Interventions

  • BiologicalSS109

    27 patients are enrolled in cohorts ,and will continue to be followed up until 28 days after SS109 administration for evaluating safety, PK/PD and immunogenicity.

06

What researchers measure

Primary outcomes

  1. The incidence of adverse event/serious adverse event/specical interest adverse event(AE/SAE/AESI)

    AE/SAE/AESI is any untoward clinical signs, symptoms or outcomes

    Time frame: Up to 28 days after SS109 injected

  2. Number of patients with positive FVII inhibitor, anti- drug antibody (ADA)

    Number of patients with positive FVII inhibitor, anti drug antibody (ADA)

    Time frame: Up to 28 days after SS109 injected

Secondary outcomes

  1. t½

    Half-life

    Time frame: Up to 72 hours after SS109 injected

  2. Cmax

    Maximum concentration

    Time frame: Up to 72 hours after SS109 injected

  3. Tmax

    Time to reach maximum concentration

    Time frame: Up to 72 hours after SS109 injected

  4. AUC0-last

    Area under the curve from 0 to last

    Time frame: Up to 72 hours after SS109 injected

  5. AUC0-72

    Area under the curve from 0 to 72 hour

    Time frame: Up to 72 hours after SS109 injected

  6. AUC0-∞

    Area under the curve from 0 to ∞

    Time frame: Up to 72 hours after SS109 injected

  7. CL

    Clearance

    Time frame: Up to 72 hours after SS109 injected

  8. Vd

    Volume of distribution

    Time frame: Up to 72 hours after SS109 injected

  9. MRT

    Mean residence time

    Time frame: Up to 72 hours after SS109 injected

  10. IR

    Incremental recovery rate

    Time frame: Up to 72 hours after SS109 injected

Other outcomes

  1. PT

    Prothrombin time

    Time frame: Up to 72 hours after SS109 injected

  2. aPTT

    activated partial thromboplastin time

    Time frame: Up to 72 hours after SS109 injected

  3. TGA

    thrombin generation test

    Time frame: Up to 72 hours after SS109 injected

  4. TAT

    thrombin antithrombin complex

    Time frame: Up to 72 hours after SS109 injected

07

Study locations

10 sites
  • Anhui Provincial Hospital
    Hefei, Anhui, China
  • Henan Provincial Cancer Hospital
    Zhengzhou, Henan, China
  • Xiangya Hospital, Central South University
    Changsha, Hunan, China
  • Affiliated Hospital of Xuzhou Medical University
    Xuzhou, Jiangsu, China
  • Jiangxi Provincial People's Hospital
    Nanchang, Jiangxi, China
  • The First Affiliated Hospital of Shandong First Medical University
    Jinan, Shandong, China
  • The Second Hospital of Shanxi Medical University
    Taiyuan, Shanxi, China
  • Xi'an Central Hospital
    Xi'an, Shanxi, China
  • Hematology Hospital, Chinese Academy of Medical Sciences
    Tianjin, Tianjin, China
  • The Second Affiliated Hospital of Kunming Medical University
    Kunming, Yunnan, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2022 to primary completion in Mar 2023, 3 months.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 29, 2022
First posted
Dec 14, 2022
StartActual
Dec 14, 2022
Primary completionActual
Mar 31, 2023
CompletionActual
Aug 15, 2023
Last update
Aug 22, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 22, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05651061
Lead sponsor
Jiangsu Gensciences lnc.
Responsible party
Sponsor
First posted
Dec 14, 2022
Start date
Dec 14, 2022
Primary completion
Mar 31, 2023
Completion
Aug 15, 2023
Last update
Aug 22, 2023

Study contacts

Renchi Yang
principal investigator · Hematology Hospital, Chinese Academy of Medical Sciences

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion